Method of treating retinal vein occlusion

• US 20110160262A1
• Filed: 02/28/2011
• Published: 06/30/2011
• Est. Priority Date: 05/17/2005
• Status: Abandoned Application

• Current Assignee: Santen Pharmaceutical Company Limited
• Original Assignee: Santen Pharmaceutical Company Limited
• Inventors: Doi, Reina, Kurose, Tatsuji, Oohashi, Kouji, Kageyama, Masaaki
• Application Number:
  US12/932,546
• Publication Number:
  US 20110160262A1
• Time in Patent Office: Days
• US Class Current: 514/392
• CPC Class Codes: A61K 31/235 having an aromatic ring attached to a carboxyl group
• CPC Class Codes: A61K 31/4168 having a nitrogen attached in position 2, e.g. clonidine
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

A method for treating retinal vein occlusion involving administering to a patient a pharmacologically effective amount of a compound represented by the following formula (II) or a salt thereof:

• • wherein R₁, R₂ and R₃ are the same or different and represent a hydrogen atom or an alkyl group, or R₁ and R₃ may be joined together to form a ring having one or more double bonds.

Claims

1. A method for treating retinal vein occlusion comprising administering to a patient a pharmacologically effective amount of a compound represented by the following formula [II] or a salt thereof:

2. The method according to claim 1, wherein the administration is carried out using an oral preparation, an injection, an eye drop, or a preparation for intraocular implant.

3. The method according to claim 1, wherein the compound represented by the formula [II] is 6′

-amidino-2′

-naphthyl-4-guanidinobenzoate or a salt thereof.

4. The method according to claim 1, wherein the compound represented by the formula [II] is 6′

-amidino-2′

-naphthyl-(4-(4,5-dihydro-1H-2-imidazolyl)amino)benzoate or a salt thereof.

5. The method according to claim 1, wherein the compound represented by the formula [II] is 6′

-amidino-2′

-naphthyl-4-guanidinobenzoate dimethanesulfonate.

6. The method according to claim 1, wherein the administering is by a topical administration to an eye.

7. The method according to claim 6, wherein the administering is by an instillation administration.

8. The method according to claim 6, wherein the administering is by an intravitreal administration.

9. The method according to claim 6, wherein the administering is by a subconjunctival administration.

10. The method according to claim 6, wherein the administering is by a sub-Tenon'"'"'s administration.

11. The method according to claim 3, wherein the administering is by a topical administration to an eye.

12. The method according to claim 11, wherein the administering is by an instillation administration.

13. The method according to claim 11, wherein the administering is by an intravitreal administration.

14. The method according to claim 11, wherein the administering is by a subconjunctival administration.

15. The method according to claim 11, wherein the administering is by a sub-Tenon'"'"'s administration.